Zymeworks Inc. (NASDAQ:ZYME) Receives $33.00 Consensus PT from Brokerages

Zymeworks Inc. (NASDAQ:ZYME) has been given an average rating of “Buy” by the seven analysts that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, one has given a buy recommendation and four have issued a strong buy recommendation on the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $33.00.

A number of equities analysts recently commented on ZYME shares. Wells Fargo & Company raised shares of Zymeworks from an “equal weight” rating to an “overweight” rating and set a $33.00 price objective for the company in a research note on Friday, December 12th. Citizens Jmp upgraded Zymeworks to a “strong-buy” rating in a research note on Wednesday, December 3rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Zymeworks in a research note on Wednesday, January 21st. Zacks Research downgraded shares of Zymeworks from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 26th. Finally, HC Wainwright upgraded shares of Zymeworks from a “hold” rating to a “strong-buy” rating in a report on Tuesday, October 14th.

Zymeworks Price Performance

Shares of ZYME stock opened at $22.51 on Friday. The company has a market capitalization of $1.68 billion, a P/E ratio of -26.80 and a beta of 1.25. The company’s 50-day simple moving average is $24.79 and its two-hundred day simple moving average is $19.80. Zymeworks has a one year low of $9.03 and a one year high of $28.49.

Zymeworks Company Profile

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. The company specializes in engineered antibody and protein therapeutics designed to address a range of unmet medical needs in oncology and other serious diseases. Through its proprietary platforms, Zymeworks aims to create novel bispecific and multispecific molecules that can simultaneously engage multiple targets and recruit immune effector functions to enhance potency and specificity.

At the core of Zymeworks’ innovation is its Azymetric™ bispecific antibody platform, which enables the design of asymmetrical bispecific antibodies with controlled assembly and high stability.